NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update
NuCana (NASDAQ: NCNA) has reported its Q2 2025 financial results and provided significant updates on its clinical development programs. The company has begun dosing patients in the expansion study of NUC-7738 combined with pembrolizumab for PD-1 inhibitor-resistant melanoma, with initial data expected in Q4 2025. The expansion will add 28 patients, bringing the total treated population to 40.
Financially, NuCana has strengthened its position through an ATM offering and financing initiatives, raising $38.4 million in gross proceeds in 2025. The company reported cash and equivalents of 拢8.4 million as of June 30, 2025, with additional 拢19.0 million raised post-quarter. These actions have extended the company's cash runway into 2029. The quarter saw a net loss of 拢24.1 million, including a 拢12.6 million warrant revaluation loss.
NuCana (NASDAQ: NCNA) ha comunicato i risultati finanziari del secondo trimestre 2025 e fornito aggiornamenti importanti sui suoi programmi clinici. L'azienda ha iniziato il dosaggio dei pazienti nello studio di estensione di NUC-7738 in combinazione con pembrolizumab per il melanoma resistente agli inibitori PD-1; i primi dati sono attesi nel quarto trimestre 2025. L'espansione aggiunger脿 28 pazienti, portando il totale a 40 pazienti trattati.
Sul fronte finanziario, NuCana ha rafforzato la propria posizione tramite un'offerta ATM e altre iniziative di finanziamento, raccogliendo $38,4 milioni di proventi lordi nel 2025. Al 30 giugno 2025 la societ脿 riportava liquidit脿 e equivalenti per 拢8,4 milioni, con ulteriori 拢19,0 milioni raccolti dopo la chiusura del trimestre. Queste operazioni hanno esteso la liquidit脿 aziendale fino al 2029. Nel trimestre si 猫 registrata una perdita netta di 拢24,1 milioni, comprensiva di una svalutazione di warrant di 拢12,6 milioni.
NuCana (NASDAQ: NCNA) ha dado a conocer sus resultados financieros del segundo trimestre de 2025 y proporcionado actualizaciones relevantes sobre sus programas cl铆nicos. La compa帽铆a ha comenzado a dosificar pacientes en el estudio de expansi贸n de NUC-7738 en combinaci贸n con pembrolizumab para melanoma resistente a inhibidores de PD-1; los primeros datos se esperan en el cuarto trimestre de 2025. La ampliaci贸n a帽adir谩 28 pacientes, elevando el total tratado a 40.
En cuanto a las finanzas, NuCana ha reforzado su posici贸n mediante una oferta ATM y otras iniciativas de financiaci贸n, recaudando $38,4 millones de ingresos brutos en 2025. Al 30 de junio de 2025 la compa帽铆a report贸 efectivo y equivalentes por 拢8,4 millones, con otros 拢19,0 millones recaudados despu茅s del trimestre. Estas medidas han ampliado la pista de caja hasta 2029. El trimestre registr贸 una p茅rdida neta de 拢24,1 millones, que incluye una p茅rdida por revalorizaci贸n de warrants de 拢12,6 millones.
NuCana (NASDAQ: NCNA)電� 2025雲� 2攵勱赴 鞛鞁れ爜鞚� 氚滍憸頃橁碃 鞛勳儊 臧滊皽 頂勲攴鸽灗鞐� 雽�頃� 欤检殧 鞐呺嵃鞚错姼毳� 鞝滉车頄堨姷雼堧嫟. 須岇偓電� PD-1 鞏奠牅鞝滌棎 雮挫劚鞚� 氤挫澊電� 頋戩儔膦呾潉 雽�靸侅溂搿� pembrolizumab瓿� 氤戩毄頃橂姅 NUC-7738 頇曥灔 鞐瓣惮鞐愳劀 頇橃瀽 韴棳毳� 鞁滌瀾頄堨溂氅�, 齑堦赴 雿办澊韯半姅 2025雲� 4攵勱赴鞐� 雮橃槵 瓴冹溂搿� 鞓堨儊霅╇媹雼�. 頇曥灔鞙茧 28氇呾潣 頇橃瀽臧� 於旉皜霅橃柎 齑� 旃橂 頇橃瀽 靾橂姅 40氇呾澊 霅╇媹雼�.
鞛鞝侅溂搿� NuCana電� ATM 瓿惦 氚� 旮绊儉 鞛愱笀 臁半嫭鞚� 韱淀暣 鞛 靸來儨毳� 臧曧檾頄堨溂氅�, 2025雲勳棎 $38.4氚彪鞚� 齑濎垬鞚�鞚� 臁半嫭頄堨姷雼堧嫟. 2025雲� 6鞗� 30鞚� 旮办 順勱笀 氚� 順勱笀靹� 鞛愳偘鞚� 拢8.4氚彪鞚挫棃瓿�, 攵勱赴 頉� 於旉皜搿� 拢19.0氚彪鞚� 頇曤炒頄堨姷雼堧嫟. 鞚措煬頃� 臁办箻電� 須岇偓鞚� 順勱笀 靻岇 鞁滌爯鞚� 2029雲勱箤歆� 鞐办灔鞁滌及鞀惦媹雼�. 頃措嫻 攵勱赴 靾滌啇鞁れ潃 拢24.1氚彪鞚挫棃鞙茧┌, 鞚挫棎電� 拢12.6氚彪鞚� 鞗岆煱韸� 鞛弶臧� 靻愳嫟鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
NuCana (NASDAQ: NCNA) a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 et fourni des mises 脿 jour importantes sur ses programmes cliniques. La soci茅t茅 a commenc茅 脿 doser des patients dans l'茅tude d'extension de NUC-7738 en association avec le pembrolizumab pour les m茅lanomes r茅sistants aux inhibiteurs de PD-1 ; les premi猫res donn茅es sont attendues au quatri猫me trimestre 2025. L'extension ajoutera 28 patients, portant le nombre total de patients trait茅s 脿 40.
Sur le plan financier, NuCana a renforc茅 sa position via une offre ATM et des initiatives de financement, levant 38,4 M$ de produits bruts en 2025. Au 30 juin 2025, la soci茅t茅 disposait de liquidit茅s et 茅quivalents de 拢8,4 M, avec 拢19,0 M suppl茅mentaires lev茅s apr猫s la cl么ture du trimestre. Ces mesures ont prolong茅 la piste de tr茅sorerie de la soci茅t茅 jusqu'en 2029. Le trimestre s'est sold茅 par une perte nette de 拢24,1 M, incluant une perte de r茅茅valuation des bons de souscription de 拢12,6 M.
NuCana (NASDAQ: NCNA) hat seine Finanzergebnisse f眉r das zweite Quartal 2025 ver枚ffentlicht und wichtige Updates zu seinen klinischen Entwicklungsprogrammen bekanntgegeben. Das Unternehmen begann mit der Dosierung von Patienten in der Erweiterungsstudie von NUC-7738 in Kombination mit Pembrolizumab bei PD-1-Inhibitor-resistentem Melanom; erste Daten werden f眉r Q4 2025 erwartet. Die Erweiterung wird 28 Patienten hinzuf眉gen und die insgesamt behandelte Population auf 40 erh枚hen.
Finanziell hat NuCana seine Position durch ein ATM-Angebot und Finanzierungsma脽nahmen gest盲rkt und im Jahr 2025 $38,4 Millionen Bruttoerl枚se erzielt. Zum 30. Juni 2025 meldete das Unternehmen Barmittel und 脛quivalente in H枚he von 拢8,4 Millionen, zudem wurden nach Quartalsende weitere 拢19,0 Millionen aufgenommen. Diese Ma脽nahmen haben die Cash-Runway bis ins Jahr 2029 verl盲ngert. Im Quartal wurde ein Nettoverlust von 拢24,1 Millionen verzeichnet, darunter ein 拢12,6 Millionen Verlust aus der Neubewertung von Warrants.
- None.
- Increased net loss of 拢24.1 million in Q2 2025 compared to 拢7.0 million in Q2 2024
- 拢12.6 million loss on warrant revaluation from May 2025 financing
Insights
NuCana strengthens financials through ATM offering while advancing melanoma and solid tumor clinical trials with upcoming catalysts.
NuCana's Q2 2025 results highlight significant progress in both clinical development and financial positioning. The company has successfully dosed the first patients in the expansion phase of their NUC-7738 study in PD-1 inhibitor-resistant melanoma, a notably difficult-to-treat patient population. This expansion will increase the cohort to 40 patients, providing more robust data to support a potential registration pathway.
The expansion study follows encouraging preliminary results showing favorable safety profiles, meaningful tumor volume reduction, and prolonged progression-free survival in patients who had previously failed on checkpoint inhibitors. These early signals are particularly promising given the limited treatment options currently available for this refractory population.
On the financial front, NuCana has executed a strategic financing approach that dramatically extends their operational runway. Through combined financing initiatives, they've raised
The company has also successfully eliminated all Series A Warrants from their May 2025 financing through a
With multiple catalysts on the horizon 鈥� including initial expansion study data for NUC-7738 in Q4 2025, final data in 2026, and additional data from the NUC-3373 combination study with pembrolizumab expected this year 鈥� NuCana has positioned itself to potentially deliver significant clinical validation while maintaining financial stability through these critical milestones.
NuCana's approach with their two lead candidates represents interesting scientific strategies in oncology. NUC-7738 is particularly notable for its dual mechanism 鈥� it both modifies gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. This comprehensive approach could potentially overcome the resistance mechanisms that limit the efficacy of PD-1 inhibitors in melanoma.
The expansion study in PD-1 inhibitor-resistant melanoma addresses a significant unmet clinical need. Approximately
Their second program, NUC-3373, takes a different but equally intriguing approach as a targeted thymidylate synthase inhibitor with immune-modulating properties. Traditional thymidylate synthase inhibitors like 5-FU have significant toxicity limitations. If NUC-3373 can deliver more targeted inhibition with an improved safety profile while simultaneously enhancing immune response through combination with pembrolizumab, it could represent a meaningful advancement for patients with various solid tumors.
The combination studies with pembrolizumab for both compounds highlight NuCana's focus on rational combination approaches rather than single-agent development. This strategy aligns with the evolving understanding that targeting multiple cancer pathways simultaneously often yields superior outcomes compared to monotherapies, particularly in treatment-resistant populations.
First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma
Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026
Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025
Strategic Execution of ATM Offering Extends Anticipated Cash Runway into 2029
EDINBURGH, United Kingdom, Aug. 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (鈥淣uCana鈥� or the 鈥淐ompany鈥�) announced financial results for the second quarter ended June 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines.
鈥淲e are pleased to announce that the first patients have been dosed on the expansion of our ongoing Phase 1/2 NuTide:701 study in patients with PD-1 inhibitor-resistant melanoma,鈥� said Andrew Kay, NuCana鈥檚 Executive Chairman. 鈥淥ur lead program, NUC-7738 is a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. We remain encouraged by the clinical observations witnessed so far. We have observed a favorable safety profile, meaningful tumor volume reduction and prolonged progression free-survival in patients with PD-1 inhibitor refractory and resistant metastatic melanoma. The expansion study is expected to enroll an additional 28 patients, increasing the planned patient population treated in combination with pembrolizumab to 40 and further supporting our registrational path.鈥�
Mr. Kay continued, 鈥淭urning to our second program, NUC-3373 is a targeted thymidylate synthase inhibitor with immune modulating properties. We are encouraged by the data from the Phase 1b/2 NuTide:303 study, which is evaluating NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors, and NUC-3373 with docetaxel in patients with lung cancer. Notable tumor volume reductions and prolonged progression free survival have been observed in these patients so far. We look forward to announcing additional data from this study later this year.鈥�
Mr. Kay concluded, 鈥淟astly, we strengthened our balance sheet with a financing in May and the strategic execution of an at-the-market (鈥淎TM鈥�) offering, extending our cash runway into 2029 and through key value-driving milestones. To date in 2025, these initiatives have raised gross proceeds of
Anticipated Milestones
- NUC-7738
- Announce initial data from the Phase 1/2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab in 2025;
- Obtain regulatory guidance from the U.S. Food and Drug Administration on pivotal study design for NUC-7738 in melanoma in 2026; and
- Announce final data from the Phase 1/2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab in 2026.
- Announce initial data from the Phase 1/2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab in 2025;
- NUC-3373
- Announce additional data from the Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with pembrolizumab in patients with solid tumors in 2025.
Second Quarter 2025 Financial Highlights and Cash Position
As of June 30, 2025, NuCana had cash and cash equivalents of
On July 21, 2025, having raised the full amount of capital required, NuCana announced it had successfully canceled all remaining Series A Warrants issued in the May 2025 financing, in exchange for payments of
NuCana expects that its cash and cash equivalents as of June 30, 2025, together with amounts raised via the ATM offering, will be sufficient to fund its planned operations into 2029.
NuCana continues to advance its clinical programs and reported a net loss of
About NuCana
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana鈥檚 pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Forward-Looking Statements
This press release may contain 鈥渇orward-looking鈥� statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of the Company. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company鈥檚 planned and ongoing clinical studies for the Company鈥檚 product candidates and the potential advantages of those product candidates, including NUC-7738 and NUC-3373; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company鈥檚 goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company鈥檚 current cash and cash equivalents to fund its planned operations into 2029. In some cases, you can identify forward-looking statements by terminology such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥渁nticipates,鈥� 鈥渂elieves,鈥� 鈥渆stimates,鈥� 鈥減redicts,鈥� 鈥減otential鈥� or 鈥渃ontinue鈥� or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company鈥檚 actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to raise additional capital sufficient to fund our planned operations and the risks and uncertainties set forth in the 鈥淩isk Factors鈥� section of the Company鈥檚 Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission (鈥淪EC鈥�) on March 20, 2025, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company鈥檚 beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.
Unaudited Condensed Consolidated Statements of Operations
| 听 | 听 | For the Three Months Ended June 30, | 听 | For the Six Months Ended June 30, | ||||||
| 听 | 听 | 听 | ||||||||
| 听 | 听 | 2025 | 听 | 2024 | 听 | 听 | 2025 | 听 | 2024 | 听 |
| 听 | 听 | (in thousands, except per share data) | ||||||||
| 听 | 听 | 拢 | 听 | 拢 | 听 | 听 | 拢 | 听 | 拢 | 听 |
| Research and development expenses | 听 | (7,104 | ) | (6,769 | ) | 听 | (8,829 | ) | (13,552 | ) |
| Administrative expenses | 听 | (4,523 | ) | (1,509 | ) | 听 | (5,590 | ) | (3,090 | ) |
| Net foreign exchange (losses) gains | 听 | (202 | ) | (74 | ) | 听 | (261 | ) | 21 | 听 |
| Operating loss | 听 | (11,829 | ) | (8,352 | ) | 听 | (14,680 | ) | (16,621 | ) |
| Finance income | 听 | 35 | 听 | 85 | 听 | 听 | 60 | 听 | 211 | 听 |
| Finance expense | 听 | (12,648 | ) | - | 听 | 听 | (12,648 | ) | - | 听 |
| Loss before tax | 听 | (24,442 | ) | (8,267 | ) | 听 | (27,268 | ) | (16,410 | ) |
| Income tax credit | 听 | 328 | 听 | 1,272 | 听 | 听 | 681 | 听 | 2,577 | 听 |
| Loss for the period | 听 | (24,114 | ) | (6,995 | ) | 听 | (26,587 | ) | (13,833 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||
| Basic and diluted loss per ordinary share | 听 | (0.00 | ) | (0.12 | ) | 听 | (0.01 | ) | (0.25 | ) |
Unaudited Condensed Consolidated Statements of Financial Position As At
| 听 | 听 | June 30, 2025 | 听 | December听31, 2024 | 听 | |
| 听 | 听 | (in thousands) | ||||
| 听 | 听 | 拢 | 拢 | |||
| Assets | 听 | 听 | 听 | |||
| Non-current assets | 听 | 听 | 听 | |||
| Intangible assets | 听 | 2,199 | 听 | 听 | 2,199 | 听 |
| Property, plant and equipment | 听 | 178 | 听 | 听 | 197 | 听 |
| Deferred tax asset | 听 | 112 | 听 | 听 | 113 | 听 |
| 听 | 听 | 2,489 | 听 | 听 | 2,509 | 听 |
| Current assets | 听 | 听 | 听 | |||
| Prepayments, accrued income and other receivables | 听 | 1,020 | 听 | 听 | 922 | 听 |
| Current income tax receivable | 听 | 4,266 | 听 | 听 | 4,594 | 听 |
| Cash and cash equivalents | 听 | 8,443 | 听 | 听 | 6,749 | 听 |
| 听 | 听 | 13,729 | 听 | 听 | 12,265 | 听 |
| Total assets | 听 | 16,218 | 听 | 听 | 14,774 | 听 |
| 听 | 听 | 听 | 听 | |||
| Equity and liabilities | 听 | 听 | 听 | |||
| Capital and reserves | 听 | 听 | 听 | |||
| Share capital and share premium | 听 | 171,673 | 听 | 听 | 151,827 | 听 |
| Other reserves | 听 | 86,407 | 听 | 听 | 78,421 | 听 |
| Accumulated deficit | 听 | (250,696 | ) | 听 | (224,294 | ) |
| Total equity attributable to equity holders of the Company | 听 | 7,384 | 听 | 听 | 5,954 | 听 |
| 听 | 听 | 听 | 听 | |||
| Non-current liabilities | 听 | 听 | 听 | |||
| Provisions | 听 | 58 | 听 | 听 | 37 | 听 |
| Lease liabilities | 听 | 79 | 听 | 听 | 117 | 听 |
| 听 | 听 | 137 | 听 | 听 | 154 | 听 |
| Current liabilities | 听 | 听 | 听 | |||
| Trade payables | 听 | 1,098 | 听 | 听 | 2,705 | 听 |
| Payroll taxes and social security | 听 | 185 | 听 | 听 | 134 | 听 |
| Accrued expenditure | 听 | 4,735 | 听 | 听 | 5,714 | 听 |
| Lease liabilities | 听 | 75 | 听 | 听 | 73 | 听 |
| Provisions | 听 | - | 听 | 听 | 40 | 听 |
| Derivative financial instruments | 听 | 2,604 | 听 | 听 | - | 听 |
| 听 | 听 | 8,697 | 听 | 听 | 8,666 | 听 |
| Total liabilities | 听 | 8,834 | 听 | 听 | 8,820 | 听 |
| Total equity and liabilities | 听 | 16,218 | 听 | 听 | 14,774 | 听 |
| 听 | 听 | 听 | 听 | |||
Unaudited Condensed Consolidated Statements of Cash Flows
| 听 | For听the听Six听Months听Ended June 30, | ||||
| 听 | 听听听听听听听听2025听听听听听听听听 | 听 | 听 | 听听听听听听听听2024听听听听听 | 听 |
| 听 | (in thousands) | ||||
| 听 | 拢 | 拢 | |||
| Cash flows from operating activities | 听 | 听 | |||
| Loss for the period | (26,587 | ) | 听 | (13,833 | ) |
| Adjustments for: | 听 | 听 | |||
| Income tax credit | (681 | ) | 听 | (2,577 | ) |
| Amortization and depreciation | 136 | 听 | 听 | 272 | 听 |
| Movement in provisions | (40 | ) | 听 | - | 听 |
| Finance income | (60 | ) | 听 | (211 | ) |
| Finance expense | 12,648 | 听 | 听 | - | 听 |
| Interest expense on lease liabilities | 5 | 听 | 听 | 10 | 听 |
| Share-based payments | 8,247 | 听 | 听 | 1,292 | 听 |
| Net foreign exchange losses (gains) | 387 | 听 | 听 | (112 | ) |
| 听 | (5,945 | ) | 听 | (15,159 | ) |
| Movements in working capital: | 听 | 听 | |||
| (Increase) decrease in prepayments, accrued income and other receivables | (113 | ) | 听 | 625 | 听 |
| (Decrease) increase in trade payables | (1,607 | ) | 听 | 2,734 | 听 |
| (Decrease) increase in payroll taxes, social security and accrued expenditure | (929 | ) | 听 | 725 | 听 |
| Movements in working capital | (2,649 | ) | 听 | 4,084 | 听 |
| Cash used in operations | (8,594 | ) | 听 | (11,075 | ) |
| Net income tax received | 999 | 听 | 听 | 4,015 | 听 |
| Net cash used in operating activities | (7,595 | ) | 听 | (7,060 | ) |
| Cash flows from investing activities | 听 | 听 | |||
| Interest received | 57 | 听 | 听 | 218 | 听 |
| Payments for property, plant and equipment | - | 听 | 听 | (3 | ) |
| Payments for intangible assets | (96 | ) | 听 | (176 | ) |
| Net cash (used in) from investing activities | (39 | ) | 听 | 39 | 听 |
| Cash flows from financing activities | 听 | 听 | |||
| Payments for lease liabilities | (41 | ) | 听 | (127 | ) |
| Proceeds from exercise of share options | 1 | 听 | 听 | 3 | 听 |
| Proceeds from issue of share capital | 1,222 | 听 | 听 | 1,492 | 听 |
| Proceeds from exercise of warrants | 4,436 | 听 | 听 | - | 听 |
| Proceeds from issue of warrants | 4,439 | 听 | 听 | - | 听 |
| Share issue expenses | (296 | ) | 听 | (45 | ) |
| Net cash from financing activities | 9,761 | 听 | 听 | 1,323 | 听 |
| Net increase (decrease) in cash and cash equivalents | 2,127 | 听 | 听 | (5,698 | ) |
| Cash and cash equivalents at beginning of period | 6,749 | 听 | 听 | 17,225 | 听 |
| Effect of exchange rate changes on cash and cash equivalents | (433 | ) | 听 | 112 | 听 |
| Cash and cash equivalents at end of period | 8,443 | 听 | 听 | 11,639 | 听 |
| 听 | 听 | 听 | |||
For more information, please contact:
NuCana plc
Andrew Kay
Executive Chairman
+44 131-357-1111
ICR Healthcare
Chris Brinzey
+1 339-970-2843
FAQ
What were NuCana's (NCNA) key financial results for Q2 2025?
What is the status of NuCana's NUC-7738 clinical trial expansion?
How long will NuCana's current cash runway last?
What are the upcoming milestones for NuCana's clinical programs?
How did NuCana address its warrant situation from the May 2025 financing?
